Search

Your search keyword '"Zammarchi L."' showing total 16 results
Start Over Author "Zammarchi L." Language undetermined
16 results on '"Zammarchi L."'

1. StrongNet: An International Network to Improve Diagnostics and Access to Treatment for Strongyloidiasis Control

Author

Albonico, M, Becker, SL, Odermatt, P, Angheben, A, Anselmi, M, Amor, A, Barda, B, Buonfrate, D, Cooper, P, Gétaz, L, Keiser, J, Khieu, V, Montresor, A, Muñoz, J, Requena-Méndez, A, Savioli, L, Speare, R, Steinmann, P, van Lieshout, L, Utzinger, J, Bisoffi, Z, Ault, S, Bartoloni, A, Bottazzi, ME, Bottieau, E, Bradbury, R, Brattig, N, Calleri, G, Castel, M, Caumes, E, Chiodini, PL, Colli, E, de los Santos, JJ, Einsiedel, L, Ferrero, L, Formenti, F, Forrer, A, Gobbi, F, Gombe-Goetz, S, Gomez, J, Gotuzzo, E, Guevara, A, Kearns, T, Knopp, S, Kotze, A, Krolewiecki, A, Lammie, P, Luchanez, A, Magnussen, P, Marcos, L, Marlais, T, Marti, H, McCarthy, J, Mejia, R, Mena, MA, Mertens, P, Miles, M, Molina, I, Mueller, A, Muth, S, Neumayr, A, Nickel, B, Nutman, T, Olsen, A, Page, W, Perandin, F, Periago, MV, Phongluxa, K, Polman, K, Raso, G, Saboya, M, Sayasone, S, Seixas, J, Sevcsik, AM, Schär, F, Sheorey, H, Shield, Jennifer, Arandes, AS, Steer, A, Streit, A, Tanaka, T, Vercruysse, J, Verdonck, K, Visser, L, Vonghachack, Y, Weber, C, Yajima, A, and Zammarchi, L

Subjects
Uncategorized
Abstract

No description supplied

Published
2021
Full Text
View/download PDF

3. Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data

Author

Lingscheid T, Kurth F, Clerinx J, Marocco S, Trevino B, Schunk M, Muñoz J, Gjørup IE, Jelinek T, Develoux M, Fry G, Jänisch T, Schmid ML, Bouchaud O, Puente S, Zammarchi L, Mørch K, Björkman A, Siikamäki H, Neumayr A, Nielsen H, Hellgren U, Paul M, Calleri G, Kosina P, Myrvang B, Ramos JM, Just-Nübling G, Beltrame A, Saraiva da Cunha J, Kern P, Rochat L, Stich A, Pongratz P, Grobusch MP, Suttorp N, Witzenrath M, Hatz C, Zoller T, and TropNet Schistosomiasis Investigator Group

Abstract

Schistosomiasis remains one of the most prevalent parasitic diseases worldwide and the infection is frequently found in travelers and migrants. The European Network for Tropical Medicine and Travel Health conducted a sentinel surveillance study on imported schistosomiasis between 1997 and 2010. This report summarizes epidemiological and clinical data from 1,465 cases of imported schistosomiasis. Direct pathogen detection and serology were the main diagnostic tools applied. Of these, 486 (33%) cases were identified among European travelers, 231 (16%) among long-term expatriates, and 748 (51%) among non-European immigrants. Overall, only 18.6% of travelers had received pretravel advice; 95% of infections were acquired in the African region. On species level, Schistosoma mansoni was identified in 570 (39%) and Schistosoma haematobium in 318 (22%) cases; 57.5% of patients were symptomatic. Acute symptoms were reported in 27% of patients leading to earlier presentation within 3 months. Praziquantel was used in all patients to treat schistosomiasis. Many infections were detected in asymptomatic patients. In 47.4% of asymptomatic patients infection was detected by microscopy and in 39% by serology or antigen testing. Schistosomiasis remains a frequent infection in travelers and migrants to Europe. Travelers should be made aware of the risk of schistosomiasis infection when traveling to sub-Saharan Africa. Posttravel consultations particularly for returning expatriates are useful given the high potential for detecting asymptomatic infections.

Published
2017

4. Imported dengue fever in Tuscany, Italy, in the period 2006 to 2012

Author

Lagi, F, Zammarchi, L, Strohmeyer, M, Bartalesi, F, Mantella, A, Meli, M, Blanc, P, Tacconi, D, Farese, A, Zanelli, G, Pippi, F, Aquilini, D, Tonziello, A, Nencioni, C, Benvenuti, M, Moneta, S, Furnari, F, Ciufolini, Mg, Nicoletti, L, and Bartoloni, A.

Subjects
Dengue Fever
Published
2014

9. High prevalence of clustered tuberculosis cases in Peruvian migrants in Florence, Italy

Author

Zammarchi, L., Tortoli, E., Borroni, E., Bartalesi, F., Strohmeyer, M., Baretti, S., Simonetti, M. T., Liendo, C., Santini, M. G., Rossolini, G. M., Gotuzzo, E., Bartoloni, A., Bonati, M., Pandolfini, C., Severino, F., Confalonieri, V., Tognoni, G., Bisoffi, Z., Buonfrate, D., Angheben, A., Albonico, M., Muñoz, J., ANA REQUENA MENDEZ, Roura, M., Ventura, L., Pool, R., Pell, C., Hardon, A., Chiodini, P., Moreira, J., Anselmi, M., Sempértegui, R., Mena, M. A., Garcia, H. H., Bustos, J., Santivañez, S., Torrico, F., Lozano, D., Cabrera, T. H., Morón, J. O., Cuellar, I. A., Suarez, J. A., Rojas, G. C., Nicoletti, A., and Bruno, E.

15. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

Author

Valerio Del Bono, Massimo Costantini, Andrea Angheben, Lorenzo Zammarchi, Luisa Savoldi, Caterina Turrà, Elisabetta Teopompi, Renato Pascale, Carlo Salvarani, Paolo Luigi Colombelli, Silvio Cavuto, Marco Massari, Luca Braglia, Mario Salio, Giovanni Dolci, Giovanni Secondo, Angelina Passaro, Nicola Duccio Salerno, Walter O Inojosa, Lorenzo Donghi, Giovanni Cenderello, Ombretta Para, Domenico Franco Merlo, Fabrizio Boni, Mauro Codeluppi, Pier Ferruccio Ballerini, Norbiato Claudio, Nicola Facciolongo, Paolo Bruzzi, Marco Falcone, Ilaria Piazza, Alessandro Brignone, Pier Paolo Sainaghi, Pier Giorgio Scotton, Viviana Ravagnani, Roberto Sciascia, Maurizio Milesi, Perla Bertomoro, Salvarani C., Dolci G., Massari M., Merlo D.F., Cavuto S., Savoldi L., Bruzzi P., Boni F., Braglia L., Turra C., Ballerini P.F., Sciascia R., Zammarchi L., Para O., Scotton P.G., Inojosa W.O., Ravagnani V., Salerno N.D., Sainaghi P.P., Brignone A., Codeluppi M., Teopompi E., Milesi M., Bertomoro P., Claudio N., Salio M., Falcone M., Cenderello G., Donghi L., Del Bono V., Colombelli P.L., Angheben A., Passaro A., Secondo G., Pascale R., Piazza I., Facciolongo N., and Costantini M.

Subjects
Male, Blood Gas Analysi, 01 natural sciences, law.invention, chemistry.chemical_compound, Economica, 0302 clinical medicine, Randomized controlled trial, law, Interquartile range, Fraction of inspired oxygen, Monoclonal, Receptors, Medicine, 030212 general & internal medicine, Hospital Mortality, Humanized, Original Investigation, Respiration, Aged, Antibodies, Monoclonal, Humanized, Blood Gas Analysis, C-Reactive Protein, COVID-19, Disease Progression, Early Termination of Clinical Trials, Female, Fever, Hospitalization, Humans, Intensive Care Units, Italy, Medical Futility, Middle Aged, Receptors, Interleukin-6, Respiration, Artificial, Respiratory Insufficiency, SARS-CoV-2, Intensive care unit, Artificial, Human, medicine.medical_specialty, Randomization, Intensive Care Unit, Socio-culturale, Antibodies, Early Termination of Clinical Trial, 03 medical and health sciences, Tocilizumab, Internal medicine, Internal Medicine, 0101 mathematics, Interleukin-6, business.industry, 010102 general mathematics, medicine.disease, Interim analysis, COVID-19 Drug Treatment, Pneumonia, chemistry, business
Abstract

IMPORTANCE: The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile. OBJECTIVE: To evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS: Prospective, open-label, randomized clinical trial that randomized patients hospitalized between March 31 and June 11, 2020, with COVID-19 pneumonia to receive tocilizumab or standard of care in 24 hospitals in Italy. Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab. Eligibility criteria included COVID-19 pneumonia documented by radiologic imaging, partial pressure of arterial oxygen to fraction of inspired oxygen (Pao(2)/Fio(2)) ratio between 200 and 300 mm Hg, and an inflammatory phenotype defined by fever and elevated C-reactive protein. INTERVENTIONS: Patients in the experimental arm received intravenous tocilizumab within 8 hours from randomization (8 mg/kg up to a maximum of 800 mg), followed by a second dose after 12 hours. Patients in the control arm received supportive care following the protocols of each clinical center until clinical worsening and then could receive tocilizumab as a rescue therapy. MAIN OUTCOME AND MEASURES: The primary composite outcome was defined as entry into the intensive care unit with invasive mechanical ventilation, death from all causes, or clinical aggravation documented by the finding of a Pao(2)/Fio(2) ratio less than 150 mm Hg, whichever came first. RESULTS: A total of 126 patients were randomized (60 to the tocilizumab group; 66 to the control group). The median (interquartile range) age was 60.0 (53.0-72.0) years, and the majority of patients were male (77 of 126, 61.1%). Three patients withdrew from the study, leaving 123 patients available for the intention-to-treat analyses. Seventeen patients of 60 (28.3%) in the tocilizumab arm and 17 of 63 (27.0%) in the standard care group showed clinical worsening within 14 days since randomization (rate ratio, 1.05; 95% CI, 0.59-1.86). Two patients in the experimental group and 1 in the control group died before 30 days from randomization, and 6 and 5 patients were intubated in the 2 groups, respectively. The trial was prematurely interrupted after an interim analysis for futility. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and Pao(2)/Fio(2) ratio between 200 and 300 mm Hg who received tocilizumab, no benefit on disease progression was observed compared with standard care. Further blinded, placebo-controlled randomized clinical trials are needed to confirm the results and to evaluate possible applications of tocilizumab in different stages of the disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04346355; EudraCT Identifier: 2020-001386-37

Published
2020

16. Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya

Author

G. Borgia, G. B. Gaeta, I. gentile, N. Coppola, L. Alessio, G. Angarano, S. Babudieri, A. Bartoloni, F. Borgia, F. Borrelli, G. Brancaccio, A. R. Buonomo, B. S. Cacopardo, A. Cascio, C. Contini, S. Esposito, M. Fasano, M. Foggia, M. Gatti, V. Gentile, M. Macera, A. E. Maraolo, A. Marino, C. M. Mastroianni, C. Mussini, G. Nunnari, L. Onorato, M. Pacenti, G. F. Pellicanò, B. Pinchera, G. Pipitone, M. A. Pisaturo, C. Sagnelli, T. A. Santantonio, A. Santoro, A. Saracino, M. Spaziante, M. Spinicci, M. Stanzione, G. Stornaiuolo, G. Taliani, G. Tosone, C. Torti, P. Viale, L. Zammarchi, E. Zappulo, G. Borgia, G.B. Gaeta, I. Gentile, N. Coppola, Borgia, G., Gaeta, G. B., Gentile, I., Coppola, N., Alessio, L., Angarano, G., Babudieri, S., Bartoloni, A., Borgia, F., Borrelli, F., Brancaccio, G., Buonomo, A. R., Cacopardo, B. S., Cascio, A., Contini, C., Esposito, S., Fasano, M., Foggia, M., Gatti, M., Gentile, V., Macera, M., Maraolo, A. E., Marino, A., Mastroianni, C. M., Mussini, C., Nunnari, G., Onorato, L., Pacenti, M., Pellicanò, G. F., Pinchera, B., Pipitone, G., Pisaturo, M. A., Sagnelli, C., Santantonio, T. A., Santoro, A., Saracino, A., Spaziante, M., Spinicci, M., Stanzione, M., Stornaiuolo, G., Taliani, G., Tosone, G., Torti, C., Viale, P., Zammarchi, L., and Zappulo, E.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results